Dr. Weiqi Rong 荣维淇
Chief Physician
Department of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and surgical treatment of tumors of the stomach, intestines, pancreas, and liver.
Dr. Rong graduated from Beijing Medical University in 1997 and earned a medical master’s degree from Peking Union Medical College in 2004. With over 10 years of clinical experience in abdominal tumor surgery, Dr. Rong has published more than 20 papers in core journals, contributed to books on tumor diagnosis and treatment, and participated in multiple research projects, including national-level initiatives.
Name order: in Chinese the family name comes first (Rong Weiqi). Papers usually list the name as Weiqi Rong or Rong W.
Selected publications
60 papers on PubMed matched by name and affiliation; 16 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Mol Sci, 2024 (senior author): The Role of Metabolic Reprogramming in the Tumor Immune Microenvironment: Mechanisms and Opportunities for Immunotherapy in Hepatocellular Carcinoma. PubMed 38891772
- Cancer Med, 2024 (senior author): Identification of molecular characteristics of hepatocellular carcinoma with microvascular invasion based on deep targeted sequencing. PubMed 38572921
- World J Gastroenterol, 2024 (senior author): Telomerase-related advances in hepatocellular carcinoma: A bibliometric and visual analysis. PubMed 38577190
- BMC Med, 2023 (senior author): Noninvasive urinary protein signatures combined clinical information associated with microvascular invasion risk in HCC patients. PubMed 38049860
- World J Gastrointest Surg, 2023 (senior author): High spindle and kinetochore-associated complex subunit-3 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma. PubMed 37701707
- Hepatobiliary Surg Nutr, 2022 (first author): Serum metabolic effects of corn oligopeptides with 7-day supplementation on early post-surgery primary liver cancer patients: a double-blind randomized controlled trial. PubMed 36523946
- World J Gastrointest Surg, 2021 (senior author): Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma. PubMed 34754383
- Mol Ther Nucleic Acids, 2021 (senior author): Integrated analysis of the rhesus monkey liver transcriptome during development and human primary HCC AFP-related gene expression. PubMed 34484865
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion